62 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00305 | Temporin-SHf | FFFLSRIF* | Sahara frog | Apoptosis inducing | MTT assay | HepG2 | Not specified | IC50 : 32.64 ± 1.350 µM |
| dbacp00767 | A specific Eps8/EGFR Inhibitor Peptide 327 | EFLDCFQKF | A specific Eps8/EGFR Inhibitor Peptide 327 | Immune response to tumor cell recognition | Lactate dehydrogenase (LDH)-release assay | HepG2 | Human hepatocarcinoma | IC50 : 107.34 ± 11.87 μM |
| dbacp01006 | Alyteserin-2 | ILGKLLSTAAGLLSNL | Common midwife toad | Cell penetration | Cytotoxicity assay | HepG2 | Human hepatocarcinoma | LC50 : 26 µM |
| dbacp01167 | Antimicrobial peptide TsAP-2 | MQIKHLITIFFLVLIVADHCHAFLGMIPGLIGGLISAFKGRRKREITSQIEQYRNLQKREAELENLLANLPVY | Brazilian scorpion | Not specified | Cell proliferation assay | HepG2 | Human hepatocellular carcinoma | MIC : 40 µM |
| dbacp01190 | Ascaphin-8 | GFKDLLKGAAKALVKTVLF | Coastal Tailed Frog, Pacific Northwest, USA, North America | Membrane disruption and cell lysis | Lactate dehydrogenase assay | HepG2 | Liver | LD50 : 20 µM |
| dbacp01886 | Bombinins BLP-7/GH-2 | MNFKYIVAVSFLIASTYARSVKNDEQSLSQRDVLEEESLREIRGIGGALLSAGKSALKGLAKGLAEHFANGKRTAEEHEVMKRLEAVMRDLDSLDYPEEASEMETRSFNQEEIANLFTKKEKRILGPVLDLVGRALRGLLKKIG | Oriental fire-bellied toad | Anti-proliferative activity | In vitro antitumor assay | HepG2 | Human hepatoma | IC50 : 2.88 μM |
| dbacp01889 | Bombinins BLP-7/H-BO | MNFKYIIAVSFLIASTYARSVKNDEQSLSQRDVLDEESLREIRGIGGALLSAGKSALKGLAKGLAEHFANGKRTAEEHEVMKRLEAVMRDLDSLDHPEEASEKETRGFNQEEIANLFTKKEKRIIGPVLGLIGKALGGLLG | Oriental fire-bellied toad | Anti-proliferative activity | In vitro antitumor assay | HepG2 | Human hepatoma | IC50 : 2.88μM |
| dbacp01894 | BPC194 | KKLKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | HepG2 | Cervical cancer | IC50 : 46.0 ± 3 μM |
| dbacp01899 | BPC88 | KKLLKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | HepG2 | Cervical cancer | IC50 : 32.5 ± 4 μM |
| dbacp01904 | BPC96 | LKLKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | HepG2 | Cervical cancer | IC50 : 34.5 ± 2 μM |
| dbacp01909 | BPC98 | LLKKKFKKLQ | Synthetic Peptide | Inducing apoptosis | MTT assay | HepG2 | Cervical cancer | IC50 : 44.0 ± 3 μM |
| dbacp01986 | Brevinin-ALb | FLPLAVSLAANFLPKLFCKITKKC | Rufous-spotted torrent frog, China, Asia | Cell membrane disintegration | Not specified | HepG2 | Not found | Not found |
| dbacp02287 | Carbonic anhydrase 2 | MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp02293 | Carcinoembryonic antigen glypican-3 GPC3(144-152) | FVGEFFTDV | Carcinoembryonic antigen glypican-3 GPC3(144-152) | Immune response to tumor cell recognition | Cytotoxicity assay | HepG2 | Not specified | Not found |
| dbacp02587 | CTP synthase 1 | MKYILVTGGVISGIGKGIIASSVGTILKSCGLHVTSIKIDPYINIDAGTFSPYEHGEVFVLDDGGEVDLDLGNYERFLDIRLTKDNNLTTGKIYQYVINKERKGDYLGKTVQVVPHITDAIQEWVMRQALIPVDEDGLEPQVCVIELGGTVGDIESMPFIEAFRQFQFKVKRENFCNIHVSLVPQPSSTGEQKTKPTQNSVRELRGLGLSPDLVVCRCSNPLDTSVKEKISMFCHVEPEQVICVHDVSSIYRVPLLLEEQGVVDYFLRRLDLPIERQPRKMLMKWKEMADRYDRLLETCSIALVGKYTKFSDSYASVIKALEHSALAINHKLEIKYIDSADLEPITSQEEPVRYHEAWQKLCSAHGVLVPGGFGVRGTEGKIQAIAWARNQKKPFLGVCLGMQLAVVEFSRNVLGWQDANSTEFDPTTSHPVVVDMPEHNPGQMGGTMRLGKRRTLFQTKNSVMRKLYGDADYLEERHRHRFEVNPVWKKCLEEQGLKFVGQDVEGERMEIVELEDHPFFVGVQYHPEFLSRPIKPSPPYFGLLLASVGRLSHYLQKGCRLSPRDTYSDRSGSSSPDSEITELKFPSINHD | Not found | Membrane-disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp02788 | DNAtopoisomerase 2-alpha | MEVSPLQPVNEnMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTYIGSVELVTQQMWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKMSCIRVTIDPENNLISIWNNGKGIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETASREYKKMFKQTWMDnMGRAGEMELKPFNGEDYTCITFQPDLSKFKMQSLDKDIVALMVRRAYDIAGSTKDVKVFLNGNKLPVKGFRSYVDMYLKDKLDETGNSLKVIHEQVNHRWEVCLTMSEKGFQQISFVNSIATSKGGRHVDYVADQIVTKLVDVVKKKNKGGVAVKAHQVKNHMWIFVNALIENPTFDSQTKEnMTLQPKSFGSTCQLSEKFIKAAIGCGIVESILNWVKFKAQVQLNKKCSAVKHNRIKGIPKLDDANDAGGRNSTECTLILTEGDSAKTLAVSGLGVVGRDKYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKNYEDEDSLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLRHRFLEEFITPIVKVSKNKQEMAFYSLPEFEEWKSSTPNHKKWKVKYYKGLGTSTSKEAKEYFADMKRHRIQFKYSGPEDDAAISLAFSKKQIDDRKEWLTNFMEDRRQRKLLGLPEDYLYGQTTTYLTYNDFINKELILFSNSDNERSIPSMVDGLKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSSYHHGEMSLMMTIINLAQNFVGSNNLNLLQPIGQFGTRLHGGKDSASPRYIFTMLSSLARLLFPPKDDHTLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIEELAPNQYVISGEVAILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREYHTDTTVKFVVKMTEEKLAEAERVGLHKVFKLQTSLTCNSMVLFDHVGCLKKYDTVLDILRDFFELRLKYYGLRKEWLLGMLGAESAKLNNQARFILEKIDGKIIIENKPKKELIKVLIQRGYDSDPVKAWKEAQQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYLLDMPLWYLTKEKKDELCRLRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKAKGKKTQMAEVLPSPRGQRVIPRITIEMKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQRLEKKQKREPGTKTKKQTTLAFKPIKKGKKRNPWSDSESDRSSDESNFDVPPRETEPRRAATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPQKSVVSDLEADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRAAPKGTKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDDFHMDFDSAVAPRAKSVRAKKPIKYLEESDEDDLF | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp02795 | DNAtopoisomerase 2-beta | MAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLSVERVYQKKTQLEHILLRPDTYIGSVEPLTQFMWVYDEDVGMNCREVTFVPGLYKIFDEILVNAADNKQRDKnMTCIKVSIDPESNIISIWNNGKGIPVVEHKVEKVYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVETACKEYKHSFKQTWMNnMMKTSEAKIKHFDGEDYTCITFQPDLSKFKMEKLDKDIVALMTRRAYDLAGSCRGVKVMFNGKKLPVNGFRSYVDLYVKDKLDETGVALKVIHELANERWDVCLTLSEKGFQQISFVNSIATTKGGRHVDYVVDQVVGKLIEVVKKKNKAGVSVKPFQVKNHIWVFINCLIENPTFDSQTKEnMTLQPKSFGSKCQLSEKFFKAASNCGIVESILNWVKFKAQTQLNKKCSSVKYSKIKGIPKLDDANDAGGKHSLECTLILTEGDSAKSLAVSGLGVIGRDRYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKSYDDAESLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLKHGFLEEFITPIVKASKNKQELSFYSIPEFDEWKKHIENQKAWKIKYYKGLGTSTAKEAKEYFADMERHRILFRYAGPEDDAAITLAFSKKKIDDRKEWLTNFMEDRRQRRLHGLPEQFLYGTATKHLTYNDFINKELILFSNSDNERSIPSLVDGFKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSAYHHGEQALMMTIVNLAQNFVGSNNINLLQPIGQFGTRLHGGKDAASPRYIFTMLSTLARLLFPAVDDNLLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWACKLPNYDAREIVNNVRRMLDGLDPHPMLPNYKNFKGTIQELGQNQYAVSGEIFVVDRNTVEITELPVRTWTQVYKEQVLEPMLNGTDKTPALISDYKEYHTDTTVKFVVKMTEEKLAQAEAAGLHKVFKLQTTLTCNSMVLFDHMGCLKKYETVQDILKEFFDLRLSYYGLRKEWLVGMLGAESTKLNNQARFILEKIQGKITIENRSKKDLIQMLVQRGYESDPVKAWKEAQEKAAEEDETQNQHDDSSSDSGTPSGPDFNYILnMSLWSLTKEKVEELIKQRDAKGREVNDLKRKSPSDLWKEDLAAFVEELDKVESQEREDVLAGMSGKAIKGKVGKPKVKKLQLEETMPSPYGRRIIPEITAMKADASKKLLKKKKGDLDTAAVKVEFDEEFSGAPVEGAGEEALTPSVPINKGPKPKREKKEPGTRVRKTPTSSGKPSAKKVKKRNPWSDDESKSESDLEETEPVVIPRDSLLRRAAAERPKYTFDFSEEEDDDADDDDDDNNDLEELKVKASPITNDGEDEFVPSDGLDKDEYTFSPGKSKATPEKSLHDKKSQDFGNLFSFPSYSQKSEDDSAKFDSNEEDSASVFSPSFGLKQTDKVPSKTVAAKKGKPSSDTVPKPKRAPKQKKVVEAVNSDSDSEFGIPKKTTTPKGKGRGAKKRKASGSENEGDYNPGRKTSKTTSKKPKKTSFDQDSDVDIFPSDFPTEPPSLPRTGRARKEVKYFAESDEEEDDVDFAMFN | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp02922 | FACT complex subunit SSRP1 | MAETLEFNDVYQEVKGSMNDGRLRLSRQGIIFKNSKTGKVDNIQAGELTEGIWRRVALGHGLKLLTKNGHVYKYDGFRESEFEKLSDFFKTHYRLELMEKDLCVKGWNWGTVKFGGQLLSFDIGDQPVFEIPLSNVSQCTTGKNEVTLEFHQNDDAEVSLMEVRFYVPPTQEDGVDPVEAFAQNVLSKADVIQATGDAICIFRELQCLTPRGRYDIRIYPTFLHLHGKTFDYKIPYTTVLRLFLLPHKDQRQMFFVISLDPPIKQGQTRYHFLILLFSKDEDISLTLnMNEEEVEKRFEGRLTKnMSGSLYEMVSRVMKALVNRKITVPGNFQGHSGAQCITCSYKASSGLLYPLERGFIYVHKPPVHIRFDEISFVNFARGTTTTRSFDFEIETKQGTQYTFSSIEREEYGKLFDFVNAKKLNIKNRGLKEGMNPSYDEYADSDEDQHDAYLERMKEEGKIREENANDSSDDSGEETDESFNPGEEEEDVAEEFDSNASASSSSNEGDSDRDEKKRKQLKKAKMAKDRKSRKKPVEVKKGKDPNAPKRPMSAYMLWLNASREKIKSDHPGISITDLSKKAGEIWKGMSKEKKEEWDRKAEDARRDYEKAMKEYEGGRGESSKRDKSKKKKKVKVKMEKKSTPSRGSSSKSSSRQLSESFKSKEFVSSDESSSGENKSKKKRRRSEDSEEEELASTPPSSEDSASGSDE | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp03034 | Galaxamide derivative (Compound 3) | cyclo(WnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Breast cancer | IC50 : 3.98 ± 0.71 μg/mL |
| dbacp03038 | Galaxamide derivative Compound 1 | cyclo(FnMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Breast cancer | IC50 : 6.25 ± 1.03 μg/mL |
| dbacp03042 | Galaxamide derivative Compound 2 | cyclo(NAl-nMLLLnML) | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Breast cancer | IC50 : 8.42 ± 1.82 μg/mL |
| dbacp03074 | Glutathione S-transferase P | MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp03176 | H-0, Hymenochirin-1B | IKLSPETKDNLKKVLKGAIKGAIAVAKMV | Congo dwarf clawed frog | Inducing apoptosis | MTT assay | HepG2 | Not found | IC50 : 8.07 ± 0.21 μM |
| dbacp03179 | H-11 | IKLSPETKKNLKKVLKGAIKGAIAVAKMV | Synthetic construct | Inducing apoptosis | MTT assay | HepG2 | Not found | IC50 : 4.96 ± 0.43 μM |
| dbacp03182 | H-12 | IKLSKETKDNLKKVLKGAIKGAIAVAKMV | Synthetic construct | Inducing apoptosis | MTT assay | HepG2 | Not found | IC50 : 4.28 ± 0.38 μM |
| dbacp03185 | H-13 | IKLSKETKKNLKKVLKGAIKGAIAVAKMV | Synthetic construct | Inducing apoptosis | MTT assay | HepG2 | Not found | IC50 : 2.46 ± 0.32 μM |
| dbacp03188 | H-14 | IKLSKKTKKNLKKVLKGAIKGAIAVAKMV | Synthetic construct | Inducing apoptosis | MTT assay | HepG2 | Not found | IC50 : 4.54 ± 0.25 μM |
| dbacp03283 | Hc-CATH | KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL | Green paddy frog | Not specified | MTT assay | HepG2 | Liver cancer | 4.70% cell death at 200 µg/ml |
| dbacp03284 | Hc-CATH | KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL | Green paddy frog | Not specified | MTT assay | HepG2 | Prostate cancer | 4.70% cell death at 200 µg/ml |
| dbacp03299 | Histidine-rich glycoprotein | MKALIAALLLITLQYSCAVSPTDCSAVEPEAEKALDLINKRRRDGYLFQLLRIADAHLDRVENTTVYYLVLDVQESDCSVLSRKYWNDCEPPDSRRPSEIVIGQCKVIATRHSHESQDLRVIDFNCTTSSVSSALANTKDSPVLIDFFEDTERYRKQANKALEKYKEENDDFASFRVDRIERVARVRGGEGTGYFVDFSVRNCPRHHFPRHPNVFGFCRADLFYDVEALDLESPKNLVINCEVFDPQEHENINGVPPHLGHPFHWGGHERSSTTKPPFKPHGSRDHHHPHKPHEHGPPPPPDERDHSHGPPLPQGPPPLLPMSCSSCQHATFGTNGAQRHSHNNNSSDLHPHKHHSHEQHPHGHHPHAHHPHEHDTHRQHPHGHHPHGHHPHGHHPHGHHPHGHHPHCHDFQDYGPCDPPPHNQGHCCHGHGPPPGHLRRRGPGKGPRPFHCRQIGSVYRLPPLRKGEVLPLPEANFPSFPLPHHKHPLKPDNQPFPQSVSESCPGKFKSGFPQVSMFFTHTFPK | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp03310 | HLA class II histocompatibility antigen, DRB1 beta chain (Human leukocyte antigen DRB1) (HLA-DRB1) | MVCLKLPGGSSLAALTVTLMVLSSRLAFAGDTRPRFLELRKSECHFFNGTERVRYLDRYFHNQEEFLRFDSDVGEYRAVTELGRPVAESWNSQKDLLEQKRGRVDNYCRHNYGVGESFTVQRRVHPQVTVYPAKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSALTVEWRARSESAQSKMLSGVGGFVLGLLFLGAGLFIYFRNQKGHSGLQPTGFLS | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp03355 | Hymenochirin-1B | KLSPETKDNLKKVLKGAIKGAIVAKMV | Zaire dwarf clawed frog | Membrane disruption and cell lysis | Cytotoxicity assay, Cell TiterGlo Luminescent Cell viability assay | HepG2 | Liver cancer | LC50 : 22.5 ± 1.4 μM |
| dbacp03359 | Hymenochirin-1B | IKLSPETKDNLKKVLKGAIKGAIAVAKMV-NH5 | Zaire dwarf clawed frog | Induce apoptosis and cell cycle arrest | LDH release assay, MTT assay | HepG2 | Human hepatocellular carcinoma | MIC : 0 - 50 μM |
| dbacp03400 | Interferon gamma (IFN-gamma) | MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ | Chimpanzee | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp03652 | LanC-like protein 2 (Testis-specific adriamycin sensitivity protein) | MGETMSKRLKLHLGGEAEMEERAFVNPFPDYEAAAGALLASGAAEETGCVRPPATTDEPGLPFHQDGKIIHNFIRRIQTKIKDLLQQMEEGLKTADPHDCSAYTGWTGIALLYLQLYRVTCDQTYLLRSLDYVKRTLRNLNGRRVTFLCGDAGPLAVGAVIYHKLRSDCESQECVTKLLQLQRSVVCQESDLPDELLYGRAGYLYALLYLNTEIGPGTVCESAIKEVVNAIIESGKTLSREERKTERCPLLYQWHRKQYVGAAHGMAGIYYMLMQPAAKVDQETLTEMVKPSIDYVRHKKFRSGNYPSSLSNETDRLVHWCHGAPGVIHMLMQAYKVFKEEKYLKEAMECSDVIWQRGLLRKGYGICHGTAGNGYSFLSLYRLTQDKKYLYRACKFAEWCLDYGAHGCRIPDRPYSLFEGMAGAIHFLSDVLGPETSRFPAFELDSSKRD | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp03664 | Large ribosomal subunit protein mL40 | MTASVLRSISLALRPTSGLLGTWQTQLRETHQRASLLSFWELIPMRSEPLRKKKKVDPKKDQEAKERLKRKIRKLEKATQELIPIEDFITPLKFLDKARERPQVELTFEETERRALLLKKWSLYKQQERKMERDTIRAMLEAQQEALEELQLESPKLHAEAIKRDPNLFPFEKEGPHYTPPIPNYQPPEGRYNDITKVYTQVEFKR | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp04325 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Cervical cancer | Not found |
| dbacp04326 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Esophageal cancer | Not found |
| dbacp04327 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Liver cancer | Not found |
| dbacp04328 | LvHemB1 | DVNFLLHKIYGNIRY | Marine invertebrates | Inducing apoptosis | MTT assay | HepG2 | Bladder cancer | Not found |
| dbacp04594 | Mauriporin | MNKKTLLVIFFITMLIVDEVNSFKIGGFIKKLWRSKLAKKLRAKGRELLKDYANRVINGGPEEEAAVPAERRR | Fat-tailed scorpion | Induce cell apoptosis; Targets on the cell membranes and caused membrane lysis | MTT assay, Lactate dehydrogenase (LDH) Release assay | HepG2 | Human liver cancer | IC50 : 27.9 μM - 283.3 μM |
| dbacp04634 | Medusin-AS | MAFLKKSLFLVLFLGLVSLSVCEEEKRESEEEKNEQEEDDRDERSEEKRLLGMIPLAISAISALSKLG | Gliding leaf frog | Not specified | Not specified | HepG2 | Not found | LC50 : 45 μM |
| dbacp04635 | Medusin-AS (MDS-AS) | MAFLKKSLFLVLFLGLVSLSVCEEEKRESEEEKNEQEEDDRDERSEEKRLLGMIPLAISAISALSKLG | Gliding leaf frog | Not specified | Not specified | HepG2 | Not found | LC50 : 45 μM |
| dbacp04678 | MHC Class I chain-related protein | MGLGPVFLLLAGIFPFAPPGAAAEPHSLRYNLTVLSWDGSVQSGFLTEVHLDGQPFLRCDRQKCRAKPQGQWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRSSQHFYYDGELFLSQNLETEEWTMPQSSRAQTLAMNVRNFLKEDAMKTKTLYHAMHADCLQELRRYLKSGVVLRRTVPPMVNVTRSEASEGNITVTCRASGFYPWNITLSWRQDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICQGEEQRFTCYMEHSGNHSTHPVPSGKVLVLQSHWQTFHVSAVAAAAIFVIIIFYVRCCKKKTSAAEGPELVSLQVLDQHPVGTSDHRDATQLGFQPLMSDLGSTGSTEGA | Human | Immune response regulation | WST-8 assay | HepG2 | Hepatocellular carcinoma | MIC : >5 µg/mL |
| dbacp04999 | NuBCP-9 | FSRSLHSLL | Not found | Inducing apoptosis | Not specified | HepG2 | Not specified | Not found |
| dbacp05001 | NuBCP-9 (DR8) | FSRSLHSLLRRRRRRRR | Not found | Inducing apoptosis | XTT assat | HepG2 | Liver cancer | IC50 : 9.10 μM |
| dbacp05003 | Nucleophosmin | MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVEEDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDDFDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKGPSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp05015 | Oxidized purine nucleoside triphosphate hydrolase | MGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp05433 | Peptide XT-7 | GLLGPLLKIAAKVGSNLL | Western clawed frog | Membrane disruption and cell lysis | Lactate dehydrogenase assay | HepG2 | Liver cancer | LD50 : 20 µM |
| dbacp05668 | Protein GPR15LG (Antimicrobial peptide with 57 amino acid residues) (AP-57) (Antimicrobial peptide-57) (Colon-derived SUSD2 binding factor) (CSBF) (Protein GPR15 ligand) (Protein GPR15L) (Secreted protein C10orf99) | MRLLVLSSLLCILLLCFSIFSTEGKRRPAKAWSGRRTRLCCHRVPSPNSTNLKGHHVRLCKPCKLEPEPRLWVVPGALPQV | Human | Cytotoxic effects | SDS-PAGE assay | HepG2 | Colorectal cancer | Not found |
| dbacp05867 | RAC-alpha serine/threonine-protein kinase | MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp05922 | Reactive oxygen species modulator 1 | MPVAVGPYGQSQPSCFDRVKMGFVMGCAVGMAAGALFGTFSCLRIGMRGRELMGGIGKTMMQSGGTFGTFMAIGMGIRC | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp05972 | Ribosome-inactivating protein lyophyllin (EC 3.2.2.22) | ITFQGCSPARQTVITNAITRARADVRAAVSALPTKAPVSTFSTWFGVYND | Hon-shimeji | Cytotoxicity | MTT assay | HepG2 | Not found | IC50 : 489.8 μM |
| dbacp06086 | Sigma intracellular receptor 2 | MGAPATRRCVEWLLGLYFLSHIPITLFMDLQAVLPRELYPVEFRNLLKWYAKEFKDPLLQEPPAWFKSFLFCELVFQLPFFPIATYAFLKGSCKWIRTPAIIYSVHTMTTLIPILSTFLFEDFSKASGFKGQRPETLHERLTLVSVYAPYLLIPFILLIFMLRSPYYKYEEKRKKK | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp06117 | SK84 | SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK | Fruit fly | Cell membrane disintegration | MTS/PES colorimetric assay | HepG2 | Liver cancer | IC50 : 92 μM |
| dbacp06118 | SK84 | SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK | Fruit fly | Cell membrane disintegration | MTS/PES colorimetric assay | HepG2 | Breast cancer | IC50 : 92 μM |
| dbacp06124 | SK84 | SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK | Fruit fly | Destroying the cell membranes | Cell proliferation assay | HepG2 | Liver cancer | MIC : 4 – 8 mM |
| dbacp06131 | Smp24 | IWSFLIKAATKLLPSLFGGGKKDS | Venom, Israeli Gold Scorpion | Disrupt the structure and function of cell membranes | ATP release assay | HepG2 | Liver cancer | MIC : 32 μg/ml |
| dbacp06132 | Smp43 | GVWDWIKKTAGKIWNSEPVKALKSQALNAAKNFVAEKIGATPS | Venom, Israeli Gold Scorpion | Disrupt the structure and function of cell membranes | ATP release assay | HepG2 | Liver cancer | MIC : 512 μg/ml |
| dbacp06246 | Temporin-ALa | FLPIVGKLLSGLSGLL | The rufous-spotted torrent frog, China, Asia | Cell membrane disintegration | Not specified | HepG2 | Not found | Not found |
| dbacp06424 | UDP-glucuronosyltransferase 1A1 | MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQLQQRGHEIVVLAPDASLYIRDGAFYTLKTYPVPFQREDVKESFVSLGHNVFENDSFLQRVIKTYKKIKKDSAMLLSGCSHLLHNKELMASLAESSFDVMLTDPFLPCSPIVAQYLSLPTVFFLHALPCSLEFEATQCPNPFSYVPRPLSSHSDHMTFLQRVKnMLIAFSQNFLCDVVYSPYATLASEFLQREVTVQDLLSSASVWLFRSDFVKDYPRPIMPnMVFVGGINCLHQNPLSQEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH | Human | Membrane disruption | Antibody-based assay | HepG2 | Not specified | Not found |
| dbacp06602 | ZXR-1 | FKIGGFIKKLWRSKLA | Venom base | Inducing apoptosis | MTT assay | HepG2 | Not found | IC50 : 141.7 ± 12.2 µM |